Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAF312 eye drops for corneal induced chronic pain after refractive surgery
jRCT2011220008Completed
- Sponsor
- Novartis
- Start
- Jul 2022
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of SAF312 in chronic pain (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline to Week 12 in weekly mean pain severity VAS. Started Jul 2022; status: completed.
02
Drugs
SAF312
03
Conditions
chronic pain
Beyond the preview
Go deeper on jRCT2011220008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220008.